Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Huang, Kie Kyon ^a,b   Jang, Kang Won ^c   Kim, Sangwoo ^d   Kim, Han Sang ^e,f   Kim, Sung Moo ^c   Kwon, Hyeong Ju ^d   Kim, Hye Ryun ^d   Yun, Hwan Jung ^g   Ahn, Myung Ju ^h   Park, Keon Uk ⁱ   Ramnarayanan, Kalpana ^b   McPherson, John R ^b   Zhang, Shenli ^b   Rhee, Je Keun ^j   Vettore, André L ^b   Das, Kakoli ^b   Ishimoto, Takatsugu ^b   Kim, Joo Hang ^e   Koh, Yoon Woo ^d   Kim, Se Hun ^d   Choi, Eun Chang ^d   Teh, Bin Tean ^a,b,k   Rozen, Steven G ^b   Kim, Tae Min ^j   Tan, Patrick ^a,b,l   Cho, Byoung Chul ^e   more..

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c JE UK Institute for Cancer Research JEUK Co   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Brain Korea 21 Project for Medical Science   (South Korea)

^g Chungnam National University   (South Korea)

^h Sungkyunkwan University School of Medicine   (South Korea)

ⁱ Keimyung University   (South Korea)

^j The Catholic University of Korea   (South Korea)

^k DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^l GENOME INSTITUTE OF SINGAPORE   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DACOMITINIB; DNA BINDING PROTEIN; DNA DIRECTED DNA POLYMERASE; QUINAZOLINONE DERIVATIVE; REV3L PROTEIN, HUMAN; SMALL INTERFERING RNA;

CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; EXOME; GENE SILENCING; GENETICS; HEAD AND NECK NEOPLASMS; HIGH THROUGHPUT SEQUENCING; HUMAN; MUTATION; RECOMBINATION REPAIR; RNA INTERFERENCE; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CISPLATIN; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, NEOPLASM; EXOME; GENE SILENCING; HEAD AND NECK NEOPLASMS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION; QUINAZOLINONES; RECOMBINATIONAL DNA REPAIR; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84955592472     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19552     Document Type: Article

References (38)

1. Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136, E359-86 (2015).
2. Hansen, A. R. & Siu, L. L. Epidermal growth factor receptor targeting in head and neck cancer: have we been just skimming the surface? J Clin Oncol 31, 1381-3 (2013).
3. Vermorken, J. B. et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25, 2171-7 (2007).
4. Soulieres, D. et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22, 77-85 (2004).
5. Stewart, J. S. et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 27, 1864-71 (2009).
6. Abdul Razak, A. R. et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol 24, 761-9 (2013).
7. Kim, H. S. et al. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Clin Cancer Res 21, 544-52 (2015).
8. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-21 (2013).
9. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep 3, 246-59 (2013).
10. Machiels, J. P. et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 12, 333-43 (2011).
11. Colevas, A. D. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 24, 2644-52 (2006).
12. Cancer Genome Atlas, N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576-82 (2015).
13. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-8 (2013).
14. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7, 573-84 (2007).
15. Strauss, B. S. The "A" rule revisited: polymerases as determinants of mutational specificity. DNA Repair (Amst) 1, 125-35 (2002).
16. Vaisman, A., Masutani, C., Hanaoka, F. & Chaney, S. G. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. Biochemistry 39, 4575-80 (2000).
17. Teoule, R. Radiation-induced D. N. A. damage and its repair. Int J Radiat Biol Relat Stud Phys Chem Med 51, 573-89 (1987).
18. Dees, N. D. et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res 22, 1589-98 (2012).
19. Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154-7 (2011).
20. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-60 (2011).
21. Knobel, P. A., Kotov, I. N., Felley-Bosco, E., Stahel, R. A. & Marti, T. M. Inhibition of REV3 expression induces persistent DNA damage and growth arrest in cancer cells. Neoplasia 13, 961-70 (2011).
22. Chinnaiyan, P. et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65, 3328-35 (2005).
23. Wang, M. et al. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res 71, 6261-9 (2011).
24. Sharma, S. et al. REV1 and polymerase zeta facilitate homologous recombination repair. Nucleic Acids Res 40, 682-91 (2012).
25. Lange, S. S., Takata, K. & Wood, R. D. DNA polymerases and cancer. Nat Rev Cancer 11, 96-110 (2011).
26. Tanaka, T. et al. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin Cancer Res 14, 1266-73 (2008).
27. Li, L., Wang, H., Yang, E. S., Arteaga, C. L. & Xia, F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res 68, 9141-6 (2008).
28. Nowsheen, S. et al. Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer. PLoS One 6, e24148 (2011).
29. Fabbro, M., Schuechner, S., Au, W. W. & Henderson, B. R. BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention. Exp Cell Res 298, 661-73 (2004).
30. Feng, Z., Kachnic, L., Zhang, J., Powell, S. N. & Xia, F. DNA damage induces p53-dependent BRCA1 nuclear export. J Biol Chem 279, 28574-84 (2004).
31. Shachar, S. et al. Two-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals. EMBO J 28, 383-93 (2009).
32. Takata, K. & Wood, R. D. Bypass specialists operate together. EMBO J 28, 313-4 (2009).
33. Brown, A. P., Wendler, D. S., Camphausen, K. A., Miller, F. G. & Citrin, D. Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations. J Clin Oncol 26, 3987-94 (2008).
34. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-60 (2009).
35. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20, 1297-303 (2010).
36. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 31, 213-9 (2013).
37. Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 22, 568-76 (2012).
38. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38, e164 (2010).